Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL711960

COc1ccc(CCOc2cc(OCc3nccn3C)cc(-c3nc4cccnc4[nH]3)c2)cc1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
NOS1 P29475 1/20 0.36
THRB P10828 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
GAA P10253 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
FFAR1 O14842 2/20 0.34
ENPP2 Q13822 1/20 0.34
MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL709074 0.94 NAMPT (0.36) LMNANOS1THRBHCAR2TP53
Trifluoroacetic Acid SCHEMBL718789 0.94 PDE4A (0.35) FFAR1
SCHEMBL9071803 0.92 CCNB2 (0.38) DRD2DRD3THRBHCAR2TP53
Trifluoroacetic Acid SCHEMBL711889 0.90 HDAC3 (0.34) MMP13
Trifluoroacetic Acid SCHEMBL713293 0.89 MEN1 (0.36) DRD2DRD3HCAR2CASP3SENP8
Trifluoroacetic Acid SCHEMBL711504 0.87 NOS1 (0.35) NOS1MAPTFFAR1
SCHEMBL10206670 0.87 NPC1 (0.35) DRD2DRD3THRBHCAR2CASP3
SCHEMBL10206669 0.87 MEN1 (0.35) DRD2DRD3THRBTP53MAPT
Trifluoroacetic Acid SCHEMBL712705 0.86 CACNA1B (0.36) DRD2DRD3CASP3SENP8SENP6
Trifluoroacetic Acid SCHEMBL709575 0.86 SYK (0.34) NOS1MAPTCASP3SENP8SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK LMNA 4158/4885DRD2 3228/4885DRD3 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.